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Abstract: In glaucoma therapy, nanoparticles (NPs) are a favorable tool for delivering drugs to the
outflow tissues of the anterior chamber of the eye where disease development and progression take
place. In this context, a prerequisite is an efficient enrichment of NPs in the trabecular meshwork with
minimal accumulation in off-target tissues such as the cornea, lens, iris and ciliary body. We evaluated
the optimal size for targeting the trabecular meshwork by using gold NPs of 5, 60, 80 and 120 nm
with a bare surface (AuNPs) or coated with hyaluronic acid (HA-AuNPs). NPs were compared
regarding their colloidal stability, distribution in the anterior chamber of the eye ex vivo and cellular
uptake in vitro. HA-AuNPs demonstrated an exceptional colloidal stability. Even after application
into porcine eyes ex vivo, the HA coating prevented an aggregation of NPs inside the trabecular
meshwork. NPs with a diameter of 120 nm exhibited the highest volume-based accumulation in
the trabecular meshwork. Off-target tissues in the anterior chamber demonstrated an exceptionally
low gold content. Our findings are particularly important for NPs with encapsulated anti-glaucoma
drugs because a higher particle volume would be accompanied by a higher drug payload.
Keywords: glaucoma; gold nanoparticles; anterior chamber; distribution; stability; intracameral
injection; trabecular meshwork; hyaluronic acid
1. Introduction
With an estimated 60.5 million cases, glaucoma is one of the leading causes of ir-
reversible blindness worldwide [1]. Primary open-angle glaucoma (POAG) is the most
prevalent form of glaucomatous diseases [2]. Eye drops are applied as first-line treatment to
reduce the intraocular pressure (IOP), which is the major risk factor of the disease. However,
bioavailability of topically applied drugs in the anterior chamber is only about 1 to 5% [3].
Another fundamental problem is that most conventional drugs do not target the causal
pathological changes occurring in the outflow tissues [4]. Here, the trabecular meshwork
and Schlemm’s canal are affected by an increased production of extracellular matrix and a
significant stiffening of cells [4]. Therefore, it is crucial to develop new causative options to
drastically improve the therapeutic outcome. Recently, new drugs have been approved
that interfere with the fundamental pathological processes of POAG development, such
as Rho-associated protein kinase inhibitors (e.g., netarsudil and ripasudil) [5] or nitric
oxide donors (e.g., latanoprostene bunod) [6]. In addition to these small-molecule drugs,
macromolecules, such as small interfering RNA (siRNA), are discussed as an innovative
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alternative to intervene disease progression [7,8]. However, their high molecular weight,
inherent instability and strong negative charge currently prevent nucleic acids to reach a
sufficiently high bioavailability in the anterior chamber of the eye [9].
To significantly boost the availability of drugs in the outflow tissues, we and others
recently proposed nanoparticles (NPs) as a delivery system to the anterior eye [10–12]. NPs
are expected to follow the physiological outflow pathway of the aqueous humor, thereby
reaching the trabecular meshwork and Schlemm’s canal [13]. Aqueous humor is secreted
by the ciliary epithelial cells and drains from the posterior to the anterior chamber. A minor
part exits the eye through the uveoscleral pathway, while the major part of the aqueous
humor leaves the eye through the trabecular meshwork into Schlemm’s canal [14]. The
outflow resistance, responsible for the IOP, is located within the juxtacanalicular tissue
and the endothelium of Schlemm’s canal [14]. The cells of this tissues represent the target
cells of the NPs. Once arrived at the target cells, NPs have the great advantage that they
allow for an efficient cellular uptake of their therapeutic freight [15]. Macromolecular
drugs in particular, such as siRNA, would otherwise be highly unstable and not be able to
cross cellular membranes [16]. Different types of NPs for intracameral injection have been
evaluated, such as inorganic silica NPs [17] or polymer NPs like poly(lactic-co-glycolic
acid) (PLGA) [10]. A critical parameter is the size of the particles as it influences their
transport through the tissue and uptake into target cells [18]. However, in contrast to other
tissues [19], there has been no systematic approach to determine which NP size may be
optimal to maximize the amount of drug that arrives at its final destination within the
anterior chamber of the eye. A detailed characterization of the specific NP features would
be of utmost importance to create a specific and effective drug delivery system that targets
the outflow tissues. Equally important is if the NPs are eventually distributed to off-target
tissues in the anterior eye, such as the cornea, lens, iris or ciliary body.
Therefore, in this study, we systematically examined the size-dependent distribution
of NPs in the anterior eye, with a particular focus on the outflow tissues after intracameral
injection. Model gold NPs of different sizes of 5, 60, 80 and 120 nm were evaluated.
Particles with a bare surface (AuNPs) were compared to gold NPs that were modified with
hyaluronic acid (HA-AuNPs). Hyaluronic acid (HA) was chosen because it may improve
the colloidal stability of the NPs and because it is a widely used excipient in ocular dug
delivery [20,21]. The surface- and size-dependent distribution of the NPs after intracameral
injection was examined after ex vivo perfusion of porcine eyes. Additionally, to evaluate
the successful cellular uptake of the NPs, in vitro cell culture experiments were performed.
2. Materials and Methods
2.1. Materials
Spherical AuNPs with a citric acid coated surface and a size of 5, 60, 80 and 120 nm
were purchased from Nanopartz (Loveland, CO, USA). Dulbecco’s modified Eagle’s
medium (DMEM) containing 4.5 g/L glucose and 1 g/L glucose for cell culture was
obtained from Merck (Darmstadt, Germany) and fetal bovine serum (FBS) was bought
from Biowest (Nuaillé, France). Dialysis membranes (molecular weight cut-off = 25,000 and
3500 Da) were purchased from Carl Roth (Karlsruhe, Germany) and sodium hyaluronate
(HA; 13 kDa) from Lifecore Biomedicals (Chaska, Minnesota, USA). All other chemicals
were purchased from Merck (Darmstadt, Ger-many). 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was obtained from PanReac AppliChem (Darmstadt,
Germany).
2.2. Cell Culture
Primary human trabecular meshwork (hTM) cells and Schlemm’s canal (SC) cells
were fully characterized according to standard methods (PMIDs: 9727403, 29526795) and
used until passage number 8. Primary fibroblasts were used until passage 13. All pro-
cedures for collecting human tissue were according to the Declaration of Helsinki. hTM
cells, SC cells and fibroblasts were cultivated in DMEM (supplemented with 4.5 g/L glu-
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cose for fibroblasts and 1 g/L glucose for hTM and SC cells) containing 10% (v/v) FBS,
100 units/mL penicillin and 100 µg/mL streptomycin. Immortalized human TM cells
(HTM-N) were obtained from Iok-Hou Pang and Louis DeSantis (Alcon Research Labora-
tories, Fort Worth, TX, USA). They were cultured in DMEM high glucose (4.5 g/L) with
L-glutamine (0.584 g/L) and 1 mM sodium pyruvate. Human umbilical vein endothelial
cells (HUVECs) were grown in Endothelial Cell Growth Medium MV + supplements
(PromoCell, Heidelberg, Germany) with 10% FBS, 100 units/mL penicillin and 100 µg/mL
streptomycin.
2.3. Preparation of HA-Modified AuNPs
Preparation of thiolated HA: Thiol end-modified HA (HA-SH) was prepared by
reductive amination as previously described [22]. In brief, 100 mg HA (13 kDa) and
60 mg cystamine dihydrochloride were dissolved in 10 mL 0.1 M borate buffer (pH = 8.5)
containing 0.4 M NaCl and stirred for 2 h. NaBH3CN was added to the solution for a final
concentration of 200 mM and stirred at 40 ◦C for 5 days. Afterwards, 100 mM dithiothreitol
was added and stirred again for 12 h. The resulting HA-SH was dialyzed using a dialysis
membrane (MWCO = 3500 Da) against 5 L of 100 mM NaCl solution for 2 days followed by
25% ethanol for 1 day and pure water for 1 day to remove the unreacted chemicals. Finally,
the product was freeze-dried for 5 days. HA-SH was characterized using an Avance 300
NMR-spectrometer (Bruker Bio Spin, Ettlingen, Germany).
Preparation of AuNPs with a hyaluronic acid surface (HA-AuNPs): Thiol-gold chem-
istry was used for the modification of AuNPs with HA: 248 µL HA-SH solution (1 mg/mL)
was added to 2 mL AuNP dispersion and stirred for 48 h. HA-AuNPs were purified using
a dialysis membrane (MWCO = 25,000) against purified water for 72 h.
2.4. Characterization of Gold NPs
Transmission electron microscopy (TEM): To evaluate the size and the presence of
aggregates, all particle species were imaged using a 100 kV Zeiss Libra 120 electron
microscope (Carl Zeiss AG, Oberkochen, Germany) at a magnification of 80,000×. For
analysis, samples were pipetted onto carbon-coated copper grids (300 mesh; Plano, Wetzlar,
Germany) and incubated for 3 min. Excess NP dispersion was removed with a filter paper.
All grids were air-dried and stored in a desiccator until TEM analysis.
Hydrodynamic diameter and zeta potential: The size and zeta potential of all NP
species were measured with a Malvern Zetasizer Nano ZS (Malvern, Herrenberg, Germany).
All samples were measured with a 633 nm He-Ne laser at an angle of 173◦ backward scatter
(25 ◦C) in 10% Dulbecco’s Phosphate-Buffered Saline liquid (DPBS) using either polystyrene
semi-microcuvettes (dynamic light scattering; Sarstedt, Nuembrecht, Germany) or folded
capillary cells (zeta potential; Malvern, Herrenberg, Germany), respectively.
UV-Vis spectroscopy: UV-Vis spectroscopic measurements were performed with a
FluoStar Omega (BMG Labtech, Ortenberg, Germany). UV-Vis spectra of all particle types
were taken in DPBS (λ = 400 to 800 nm).
2.5. Colloidal Stability of Gold NPs
For stability analysis, gold NPs were prepared as used for the in vitro and ex vivo
experiments. For the in vitro stability test of gold NPs, particles were dispersed in DMEM
with pyruvate containing 0.35% FBS for a final gold concentration of 2750 ppb Au. For
the ex vivo stability test, gold NPs were diluted with DPBS containing 5 mM glucose for a
final gold concentration of 9390 ppb Au. The hydrodynamic diameter (z-average size) was
measured for every particle type after 0, 0.5, 4, 6 and 20 h.
2.6. Uptake of Gold NPs in Different Cell Types In Vitro
Uptake experiments were performed using all cell types and particle species. Six-well
plates were used to perform the uptake experiments. All experiments were performed at
pH 7.4. First, NP dispersions in DMEM containing 0.35% fetal bovine serum were prepared
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at a final gold concentration of 0, 550, 2750 and 5500 ppb. All samples were pre-incubated
for 1 h to induce the formation of the protein corona. Afterwards, the NP dispersions were
added to the cells. For the SC and hTM cells, the number of different concentrations was
reduced due to the rarity of these cells. Sizes of 80 nm and 120 nm gold NPs with both
surfaces were used at a concentration of c(Au) = 5500 ppb. After 6 h of incubation (37 ◦C,
5% CO2), the NP dispersion was removed, and the cells were washed twice with DPBS.
Afterwards, 3 mL of aqua regia was added to each well and incubated at 60 ◦C for 6 h. Each
sample was diluted to a final volume of 10 mL with 5% nitric acid (v/v) and Scandium
as an internal standard was added. The final concentration of the internal standard was
1 µg/mL. Inductively coupled plasma–mass spectrometry (ICP-MS) measurements were
performed with an ELAN 6000 (Perkin Elmer, Waltham, MA, United States). Experiments
were performed in independent triplicates.
2.7. Perfusion Experiments of Porcine Eyes Ex Vivo
Fresh enucleated porcine eyes were obtained from a local butcher. Eyes with visible
damage to the cornea were excluded. After removal of extraocular tissue, the porcine eyes
were submerged into the limbus in 0.89% NaCl at 35 ◦C. The perfusion procedure was
performed as previously described [10]. Particles were diluted in DPBS containing 5 mM
glucose to a final gold concentration of 9390 ppb Au. The perfusion system consisted of a
perfusion chamber and a collection chamber. The infusion needle was inserted into the
anterior chamber via the cornea and connected to the perfusion chamber. The needle was
moved through the pupil and the tip of the needle was placed in the posterior chamber. A
second needle was positioned into the anterior chamber and connected to the collection
reservoir. This drain was closed during the perfusion except during the exchange periods.
First, a volume of 4 mL gold NPs (c(Au) = 9390 ppb) was exchanged over a time period of
about 10–15 min. The NP concentration for ex vivo testing was based on analytical con-
siderations and was determined using spiked tissue samples. Higher gold concentrations
resulted in a non-linear increase of the signal, while lower gold concentrations revealed
results below the detection limit of the ICP-MS method. Afterwards, the collection drain
was closed, and the eyes were perfused with NPs at a constant pressure of 10 mmHg for 3 h.
Then, a second exchange of perfusion solution with 4 mL of a 5 mM glucose solution was
performed to remove the remaining NPs. Afterwards, unbound NPs were washed away
by perfusion with 5 mM glucose solution for 2 h. The anterior chamber of the eye was
dissected into ciliary body, cornea, iris, lens and trabecular meshwork. All tissue samples
were freeze-dried for 3 days to obtain the dry weight of each tissue sample. Experiments
were performed at least in independent triplicates. For the evaluation of NP distribution
by electron microscopy, small samples of cornea-scleral slices, containing the trabecular
meshwork, were withheld.
2.8. Electron Microscopy Examination of the Trabecular Meshwork
Porcine eyes were obtained from the ex vivo perfusion experiments. For TEM analysis,
cornea-scleral slices from one quadrant per eye were fixed in Karnovsky’s solution (2.5%
glutaraldehyde and 2.5% paraformaldehyde in a 0.1 M cacodylate buffer) for 24 h [23].
After rinsing in the 0.1 M cacodylate buffer, postfixation was accomplished in a mixture
of 1% OsO4 and 0.8% potassium ferrocyanide in a 0.1 M cacodylate buffer for 3.5 h at
48 ◦C. The eyes were then dehydrated in a graded series of ethanol and embedded in Epon
(Serva, Heidelberg, Germany). Semithin sections (1 µm) were collected on uncoated glass
slides and stained with methylene blue/azure II (LIT). Ultrathin sections were mounted
on uncoated copper grids, stained with uranyl acetate and lead citrate, and examined on
a Zeiss Libra transmission electron microscope (Carl Zeiss AG). The number of NPs in
the trabecular meshwork was quantified and related to an area of 1000 µm2. Particles
were counted in the entire trabecular meshwork and divided into the outer and inner part
of the trabecular meshwork. Particles that did not penetrate deeply into the trabecular
meshwork were attributed to the outer trabecular meshwork, while particles that were
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found deeper in the trabecular meshwork were assigned to the inner trabecular meshwork.
Images were analyzed with ImageSP (TRS, Moorenweis, Germany) and QuPath (version
0.2.3, University of Edinburgh, Edinburgh, UK).
2.9. Gold Content of the Cells and Tissue Samples
For ICP-MS measurements, each tissue sample was subjected to a microwave digestion
for 1 h at 140 to 190 ◦C in aqua regia. Subsequently, each sample was diluted to 10 mL
with 5% (v/v) nitric acid and Scandium as an internal standard at a final concentration of
1 µg/mL was added. ICP-MS-measurements were performed with an ELAN 6000 (Perkin
Elmer, Waltham, MA, USA).
2.10. Statistical Analysis
All reported data were calculated as the mean ± standard deviation of at least three
independent samples. When necessary, standard deviations were calculated according
to the rules of propagation of errors. Unpaired, two-tailed Welch’s t-tests for statistical
analyses were performed with GraphPad PRISM 6.01 software (San Diego, CA, USA) to
assess statistical significance (p < 0.05).
3. Results
3.1. Modification and Physicochemical Characterization of Gold NPs
In this study, commercially available gold NPs of different sizes were applied for
cellular uptake studies in vitro and perfusion of porcine eyes ex vivo (Scheme 1A). In all
experiments, unmodified AuNPs were compared to gold NPs carrying HA on their surface
(HA-AuNPs).
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Scheme 1. Schematic drawing of gold NPs and their modification. (A) For in vitro and ex vi o experiments, gold NPs with a
nominal size of 5, 60, 80 and 120 nm were applied. Particles were decorated with hyaluronic acid (HA-AuNPs) to determine
their physicochemical properties, cellular uptake and distribution in the anterior chamber of the eye in comparison to
AuNPs with an unmodified surface. (B) For modification, end-thiol-modified HA was synthesized and coupled to the
particles using thiol-gold chemistry.
In a first step, HA was immobilized on the surface of unmodified AuNPs. To this end,
a terminal thiol group was introduced into HA, resulting in thiolated HA. The reaction
was performed using reductive amination (Scheme 1B) [22]. 1H-NMR-spectroscopy vali-
dated the successful conversion to thiolated HA (see Supplementary Material Figure S1).
Thiolated HA was then coupled to the AuNPs via thiol-gold chemistry [24], resulting in a
partially covalent chemical bond between the thiol of HA-SH and the AuNP surface.
TEM visualized the spherical shape of all particle species. The diameters of the AuNPs
were determined to be 5.7 ± 3.7 nm, 60.8 ± 3.4 nm, 78.2 ± 4.6 nm and 119.0 ± 7.1 nm,
respectively (Figure 1A). The diameter of the modified HA-AuNPs was similar. The HA
coating did not cause any visible changes of HA-AuNPs like aggregation. As expected,
Pharmaceutics 2021, 13, 901 6 of 17
TEM did not visualize HA on the gold surface. For simplicity reasons, in the following, the
AuNPs and HA-AuNPs are denoted with a size of 5, 60, 80 and 120 nm, respectively.
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Figure 1. Physicoche ical characterization of the u Ps and - u Ps. (A) TE images de on-
strated a spherical shape of all particles. The sizes of the AuNPs were 5.7 ± 3.7 nm, 60.8 ± 3.4 nm,
78.2 ± 4.6 nm and 119.0 ± 7.1 nm, respectively. The sizes of the HA-AuNPs were 5.1 ± 2.4 nm,
64.7 ± 2.5 nm, 88.6 ± 10.2 nm and 125.1 ± 9.3 nm, respectively. There was no considerable difference
between the AuNPs and HA-AuNPs. The scale bar indicates 100 nm. (B) The SPR absorbance
maximum of the particles showed a right shift with increasing particle size. For the AuNPs, the
UV-maxima were 520 nm, 534 nm, 554 nm and 604 nm, respectively. For the HA-AuNPs, the UV-
maxima were 528 nm, 534 nm, 554 nm and 606 nm. HA surface modification caused a right-shift of
the UV-maximum only in case of the 5 nm AuNPs. (C) To illustrate the size increase after coating
with HA, the difference in the hydrodynamic diameter between the HA-AuNPs and AuNPs was
calculated. The hydrodynamic diameter differed by about 2 to 14 nm and was not statistically
significantly different. (D) The polydispersity index (PDI) decreased with increasing size and after
HA coating. (E) The zeta potential of all particle types was negative (−20 to −25 mV).
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Gold NPs have a characteristic surface plasmon resonance (SPR) absorbance in the
visible spectrum depending on their size and dielectric constant of the surrounding
medium [25]. As expected, the SPR peak shifted towards larger wavelengths with in-
creasing particle size for both AuNPs and HA-AuNPs (Figure 1B). For 5 nm AuNPs, also
a shift in the SPR peak from 520 to 528 nm was determined after coating, indicating a
successful deposition of HA. For other particle sizes, a shift after coating with HA was not
detectable.
To verify the HA coating, the hydrodynamic diameter of the particles was determined.
Values after and before coating were subtracted and expressed as size increase. As ex-
pected, the HA coating led to a slight size increase between 2 and 14 nm (Figure 1C). It
seemed that particularly the 5 nm particles showed a larger size increase after coating. The
polydispersity index (PDI) of the NPs decreased with increasing size (Figure 1D), which
means that the size distribution of the particles became narrower. In addition, HA-AuNPs
had a lower PDI compared to AuNPs. The surface zeta potential of all particle species was
around −20 to −25 mV (Figure 1E).
3.2. Colloidal Stability of Gold NPs
Another important factor for further application is the stability of the NPs in physio-
logical media because aggregation can significantly alter the physicochemical properties.
To assess the colloidal stability, AuNPs and HA-AuNPs were incubated in cell culture or
perfusion medium as it will be used subsequently either for in vitro or ex vivo studies,
respectively. Then, the hydrodynamic diameter of the particles was monitored over time
(Figure 2). In cell culture medium, HA-AuNPs did not show any significant change in
the hydrodynamic diameter, even after 20 h of incubation, while the AuNPs showed a
tremendous increase in size, indicating the presence of large aggregates (Figure 2A). In
contrast, in the perfusion medium, there was no discernable difference between the AuNPs
and HA-AuNPs (Figure 2B). Instead, both particle species demonstrated excellent colloidal
stability in the perfusion medium with the exception of 5 nm AuNPs. The enormous size
increase of 5 nm AuNPs indicated the presence of larger aggregates. To corroborate the
higher colloidal stability of the HA-AuNPs, the protein adsorption on the NP surface in
serum containing medium was investigated by using SDS-PAGE. HA-AuNPs revealed a
significantly lower protein adsorption compared to AuNPs (see Supplementary Material
Figure S2).
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Figure 2. Colloidal stability of NPs in cell culture and perfusion media. The stability of AuNPs (grey lines) and HA-AuNPs
(blue lines) was tested in cell culture medium (A) and in perfusion medium (B) over a time period of 20 h. The hydrodynamic
diameter after certain time points was related to the initial hydrodynamic diameter (t = 0 h) and reported as the relative
hydrodynamic diameter. Measurements were taken after 0, 0.5, 4, 6 and 20 h. AuNPs showed a significant increase in size
after incubation in the c ll cult re medium. HA-AuNPs did n t s ow an increase in size, indicating a higher stability in the
cell culture m dium. In perfusion medium, none of the particles showed a significant incr as in size, i dicating a sufficient
stability. An exception was the 5 nm AuNPs. Statistically significant differences between 5 nm AuNPs and 5 nm HA-AuNPs
are denoted by * or ** (p < 0.05 or p < 0.01, respectively).
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3.3. Perfusion of Porcine Eyes with Gold NPs Ex Vivo
Ex vivo perfusion of porcine eyes was performed to determine the distribution of gold
NPs in their anterior chambers. A total of 6 h after injection of the gold NPs, the anterior
chamber was dissected and the ciliary body, cornea, iris, lens and trabecular meshwork
were prepared. The gold content of each tissue sample was determined by ICP-MS and
related to the dry weight of the tissue (Figure 3). A general trend was that with increasing
particle size a higher gold content was measured. The gold content directly correlates to
the NPs´ volume. This means that with an increasing size of the applied gold NPs, the
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3.4. Distribution Pattern of Gold NPs in the Outflow Tissue 
Thereafter, the distribution of 60 and 120 HA-AuNPs within the trabecular mesh-
work was carefully investigated by TEM (Figure 5). Both particle species showed an ex-
tracellular and intracellular distribution pattern. Extracellular NPs were detected within 
the extracellular matrix (Figure 5 upper left panel) and in the so called “open spaces” of 
the fluid egress pathways (Figure 5 upper right panel). Intracellular NPs were only ob-
served in trabecular meshwork cells, but not in endothelial cells of the aqueous plexus. 
The porcine aqueous plexus is the anatomical correlate to the human Schlemm´s canal. 
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3.4. Distribution Patt rn of Gold NPs in the Outflow Tissue
Thereafter, the distribution of 60 and 120 HA-AuNPs within the trabecular meshwork
was carefully investigated by TEM (Figure 5). Both particle species showed an extracellular
and intracellular distribution pattern. Extracellular NPs were detected within the extra-
cellular matrix (Figure 5 upper left panel) and in the so called “open spaces” of the fluid
egress pathways (Figure 5 upper right panel). Intracellular NPs were only observed in
trabecular meshwork cells, but not in endothelial cells of the aqueous plexus. The porcine
aqueous plexus is the anatomical correlate to the human Schlemm´s canal.
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Table 1. Quantitative evaluation of distribution of 60 or 120 nm HA-AuNPs in TEM images. Three 
independent experiments were conducted. TM = trabecular meshwork. 
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The quantification of the NPs showed a uniform distribution in the entire trabecular
meshwork (Table 1). The comparison of distribution in the different regions revealed no
significant differences between both particle sizes. In addition, both NP sizes were found
intracellular in trabecular meshwork cells, in a similar amount (Figure 5). A difference
between both particle sizes was that the 120 nm HA-AuNPs were rather taken up by cells in
the outer trabecular meshwork, while the 60 nm HA-AuNPs were also taken up by cells in
the inner trabecular meshwork. An interesting observation was that nearly all HA-AuNPs
remained single in the tissue and did not aggregate (Table 1 and Supplementary Material
Figure S3).
Table 1. Quantitative evaluation of distribution of 60 or 120 nm HA-AuNPs in TEM images. Three
independent experiments were conducted. TM = trabecular meshwork.
Criteria 60 nm 120 nm Statistics
particles per 1000 µm2
–of total TM (±SEM)
–of outer TM (±SEM)










aggregated NPs 0 of 125 2 of 73
3.5. Cellular Uptake of Gold NPs In Vitro
To test if a certain gold NP size is also preferably taken up by their target cells, we
performed cellular uptake studies. Cultured cells from the trabecular meshwork and
Schlemm´s canal were tested (Table 2). Due to its convoluted structure, it was technically
not possible to isolate the aqueous plexus after ex vivo perfusion. Nevertheless, we
included human Schlemm´s canal cells for in vitro studies due to their importance for
glaucoma development and progression [26]. HTM-N cells were used as a trabecular
meshwork cell line. In addition, primary hTM cells from two different donors were
used. According to the literature, human umbilical vein endothelial cells (HUVECs) were
used as surrogate for Schlemm´s canal cells [27,28]. In addition, primary human cells
of the Schlemm´s canal (SC) from two different donors were applied. Last but not least,
primary human fibroblasts served as a disease model for glaucomatous cells due to the
fact that cells in the trabecular meshwork increasingly acquire the phenotype of contractile
myofibroblasts during glaucoma development [14].
Table 2. Cell types used for the cellular uptake of NPs in vitro.
Tissue/Condition Immortalized Cell Lines Primary Cells
trabecular meshwork HTM-N hTM (no. 134 and 136)
endothelial cells – SC (no. 74 and 79) HUVEC
disease model – fibroblasts
The four different sizes of gold NPs were added to the cells at three different concentra-
tions for 6 h. In the case of primary cells of the trabecular meshwork and Schlemm´s canal,
only 80 and 120 nm gold NPs at the highest concentration were evaluated. The cellular gold
content was measured by using ICP-MS (Figure 6). The gold content correlated again to
the particle volume. In the trabecular meshwork cell line, the gold content increased with
the size and the concentration of the NPs for both AuNPs and HA-AuNPs (Figure 6A). In
hTM cells, this trend was not as clear (Figure 6B,C). In HUVECs that served as a surrogate
for cells of the Schlemm´s canal, the cellular gold content increased with the size and
concentration of AuNPs, but not in the case of HA-AuNPs (Figure 6D). In contrast, when
using primary SC cells, the cellular gold content increased with the size irrespective of
the surface modification (Figure 6E,F). The fibroblast also nicely followed the pattern of a
higher gold content of the cells with increasing particle size and concentration (Figure 6G).
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cation. Therefore, the toxicity of the NPs was evaluated in an MTT assay and clearly 
Figure 6. Uptake of AuNPs and HA- uNPs into different cell types. Different cell types were used to determine the amount
of uptake of AuNPs versus HA-AuNPs. Grey bars represent the AuNPs, and blue bars represent the HA-AuNPs. For
HTM-N cells, HUVECs and fibroblasts (A,D,G), three different NP concentrations were applied (550, 2750 and 5500 ppb).
For primary hTM and SC cells (B,C,E,F), only the highest NP concentration was evaluated (5500 ppb). Larger particles
seemed to increase the uptake of gold. (A) For HTM-N cells, the gold content increased with the NP concentration and
the uptake of HA-AuNPs was tendentially higher compared to AuNPs. (B) Primary hTM134 cells did not exhibit any
significa t tendency between the different particle species. (C) Primary hTM136 cells demonstrated a hig er uptake for the
120 nm HA-AuNPs. (D) HUVEC cells showed a lower uptake of HA-AuNPs compared to AuNPs. The 120 nm AuNPs were
taken up significantly better than smaller AuNPs. (E) Primary SC74 cells displayed higher uptake ates for 120 nm AuNPs
or HA-AuNPs, compared to the corresponding 80 nm particles, respectively. (F) Primary SC79 cells showed a higher uptake
of 120 nm HA-AuNPs compared to 80 nm HA-AuNPs. (G) Fibroblasts featured a tendency to have larger particles for
both surface modifications and several particle sizes. Statistically significant differences are denoted by *, ** or *** (p < 0.05,
p < 0.01 or p < 0.001, respectively).
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Finally, the safety of the NPs is of utmost importance for possible therapeutic ap-
plication. Therefore, the toxicity of the NPs was evaluated in an MTT assay and clearly
demonstrated no significant adverse effects for all applied particle types (see Supplemen-
tary Material Figure S4).
4. Discussion
Glaucoma is a leading cause of acquired blindness and is linked to pathologic changes
in the trabecular meshwork and Schlemm´s canal [29]. For successful glaucoma treatment
and to avoid adverse events, it will be of utmost importance to deliver therapeutic agents
effectively and selectively to the trabecular meshwork. NPs may be an optimal tool for
drug delivery to the anterior eye [30], particularly when the delivery of high molecular
weight drugs is envisioned [10,17]. Because it is not known which NP size is optimal
for this purpose, in this study, we systematically analyzed the uptake and distribution of
AuNPs of different surface modifications (unmodified vs. hyaluronic acid) and sizes (5, 60,
80 and 120 nm) in the anterior chamber of the eye.
NPs for drug delivery to the anterior eye can be composed of different materials. As
yet, fluorescently labelled PLGA NPs [10] and functionalized silica NPs [17] have been
applied for intracameral injection. Polymeric NPs have the advantage that they can be
tailored to be biodegradable [31]. In contrast, inorganic NPs are usually not degradable [32].
We hypothesize that NPs that leave the anterior chamber will enter the venous circulation
via Schlemm´s canal. Depending on their size, the NPs will then be eliminated from the
circulation via the kidney or by the mononuclear phagocyte system [33]. We chose gold
NPs as a model in this study because of several advantages, including their easy surface
modification using thiol-gold chemistry, availability in different sizes, high biocompatibility
with cells and tissues [34] and low detection limits using ICP-MS. Spherical and not rod-
shaped AuNPs were used in this study because the results may then be better transferred to
lipid or polymer NPs that also have a spherical shape. Different methods were chosen for
the characterization of the particles because each one provided different information about
their physico-chemical properties. The increase in the particle size was nicely corroborated
by UV-Vis spectroscopy, which revealed a right shift of the SPR maximum with increasing
particle size. This right shift was expected due to the fact that optical absorption and
scattering is dependent on particle size and is described theoretically by Mie theory [25].
Because the SPR maximum also changes with the dielectric constant of the surrounding
medium, one could have expected a difference between the coated and uncoated particles
of the same size. However, this was only possible for the 5 nm particles. For other particle
sizes, this difference was not detected, most likely because the SPR peak broadens with
increasing particle size and then the small differences between AuNPs and HA-AuNPs
cannot be detected reliably anymore. However, with the help of dynamic light scattering,
the expected size increase of AuNPs after coating with HA was clearly demonstrated. At
the same time, the PDI of the gold NPs was reduced after coating with HA, indicating
a separation of the particles due to shielding effects [20]. 60, 80 and 120 nm particles
had a PDI of 0.2 or even lower, accounting for a narrow size distribution of the particles,
especially after HA coating. The PDI is calculated as the square of the absolute standard
deviation divided by the mean particle diameter. Consequently, size variations cause a
disproportionately higher PDI for smaller particles. The lower PDI of the HA-AuNPs
might indicate a protective effect of HA against aggregation. The surface zeta potential is
an important property of NPs as it influences unspecific binding [35]. It was negative for
both surfaces of the gold NPs, which was expected because both citrate ions on unmodified
AuNPs and HA carry negative charges.
The colloidal stability is of utmost importance for NP application. A lack of colloidal
stability leads to aggregation of NPs. Consequently, decisive properties of the particles,
such as cellular uptake, toxicity or biodistribution, can be altered significantly [36]. The
consequence of protein adsorption on the surface of NPs cannot be easily predicted because
it may influence the colloidal stability in either a positive or negative manner [37]. In
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contrast, a high ionic strength of the surrounding media usually negatively influences
the colloidal stability [38]. After incubation in cell culture medium containing 0.35%
serum, which is equal to the concentration of proteins in the aqueous humor [39], HA-
AuNPs did not show any sign of aggregation. In contrast, AuNPs did not withstand these
conditions and showed a severe tendency towards aggregation. This indicates a stabilizing
effect of HA and is also well known for polyethylene glycol (PEG)-functionalized gold
NPs [40]. In contrast, in perfusion medium, there was only a significant increase in the
5 nm AuNPs detectable. This can be attributed to the high specific surface area of these
small particles. All other particles were more or less stable, irrespective of their size and
surface modification. Generally, bare AuNPs are more stable in phosphate buffer than in
serum-containing culture medium [38]. This finding was confirmed by our study, where
the unmodified AuNPs demonstrated a higher stability in the perfusion buffer than in the
cell culture medium. In addition, the adsorbed proteins to both particle types were semi-
quantitatively compared by SDS-PAGE. This brought further evidence for the shielding
effects of HA, and because it was clearly demonstrated that the HA coating reduced the
protein adsorption significantly on the surface of the gold NPs.
The perfusion of porcine eyes was performed to study the optimal NP size for targeting
the trabecular meshwork. The results clearly illustrate that larger particles deliver a
much higher overall particle volume to the trabecular meshwork. All other tissues of the
anterior eye showed lower concentrations of gold. Particularly, the cornea and the lens
demonstrated exceptionally low gold concentrations and were comparable to the control.
This distribution pattern is beneficial for targeting the trabecular meshwork as it minimizes
the risk of off target effects, especially to the cornea, which is a natural anatomical barrier
and is therefore not expected to take up NPs at a significant level [41]. Studies assessing
the ocular biodistribution of topically applied polymeric NPs revealed a relatively low
distribution to the iris and the cornea [42]. In addition, if too many NPs end up in the
cornea or the lens, it may interfere with vision due to scattering effects [25]. Further
in vivo studies will be necessary to confirm and substantiate the results of this study. A
potential distribution of NPs from the anterior chamber to the retina and/or vitreous
body seems highly unlikely due to the physiology of the aqueous humor dynamics [43]
and was therefore not investigated in this study. In fact, the velocity of posterior fluid
movement is negligible compared to the aqueous humor flow in the anterior chamber [44].
Therefore, drugs applied to the anterior chamber are primarily eliminated through the
aqueous humor [45,46]. For targeting the trabecular meshwork, larger particles regardless
of their surface showed favorable properties. Unfortunately, unmodified 5 nm AuNPs
were prone to aggregation and therefore acted like larger particles. The uncontrolled
tendency towards aggregation makes them useless for drug delivery purposes. Even
though there was no difference between the AuNPs and HA-AuNPs for 60, 80 and 120 nm
particles, one would choose HA-AuNPs for therapeutic application due to their significantly
higher colloidal stability. Electron microscopy of tissue samples corroborated that HA
coating is beneficial because even in the trabecular meshwork the particles remained
single and did not aggregate. In our in vitro and ex vivo experiments, the measured gold
concentration directly correlated to the particle volume. Consequently, larger gold NPs lead
to a higher overall particle volume delivered to the trabecular meshwork. Generally, active
pharmaceutical ingredients can either be attached to the surface of NPs or encapsulated into
the particles’ matrix. Our findings are particularly important for NPs with encapsulated
drugs because a higher particle volume offers much more space for the drug and allows
for a much higher drug content per particle. Consequently, even if fewer larger particles
have arrived at the target tissue, they would lead to an overall higher drug amount.
The ex vivo perfusion experiments confirmed that the NPs preferentially arrived in
the target tissue in a high amount and that the 120 nm particles showed a slight superiority
compared to the smaller sizes Many drugs, such as siRNA, have their place of action inside
cells. An intracellular location of the NPs after perfusion was confirmed by TEM. Once
arrived at the target cells, NPs have the great advantage to allow for an efficient cellular
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uptake of their therapeutic freight [8]. Macromolecular drugs in particular, such as siRNA,
would otherwise be highly unstable and not be able to cross cellular membranes [9]. In
a next step, we substantiated and quantified the cellular uptake in vitro. In addition to
trabecular meshwork cells, we also chose cells of Schlemm´s canal, because these cells are
equally important for disease development and progression [47]. The trend of a higher
uptake of larger particles was demonstrated in most, but not all cell types. It was very
remarkable that primary cells showed an efficient uptake of NPs and that particularly
Schlemm´s cells showed the highest uptake rate amongst the primary cell types, which
is of utmost importance for drug delivery. Another fact of importance was the favorable
uptake of gold NPs into fibroblasts. Trabecular meshwork cells show a transformation
to myofibroblasts in the course of the disease [14]. According to our experiments, this
transformation will not impede NP uptake. However, one must keep in mind that at late-
stage glaucoma there is a significant loss of trabecular meshwork cells [48]. For application
of NPs that are envisioned to target the outflow tissues, two options are conceivable. The
NPs are injected into the anterior chamber of the eye, thereby avoiding the significant
barrier of the cornea. Regarding this application route, there is only limited literature
and clinical experience so far compared to intravitreal injections [4,49]. However, because
drug delivery devices for intracameral injection are gaining increasing attention [50,51],
guidelines on intracameral injection techniques have been provided recently [49]. Another
limitation is that frequent application intervals would be necessary because the aqueous
humor has a rapid turnover [4]. To cope with this shortcoming, a depot formulation
containing the NPs would be ideal in the long run. Such a depot would be applied
intraocularly, for example, into the vitreous body [52]. After release from the depot, the
NPs would reach the anterior chamber and be distributed to the trabecular meshwork.
Such a formulation would be more patient friendly and most likely associated with a
much higher compliance because it would reduce the application frequency dramatically.
Another location for a depot formulation would be the supraciliary space or the anterior
chamber [4].
5. Conclusions
We successfully investigated the relevance of NP size for targeting the trabecular
meshwork after intracameral injection ex vivo. Particles with a diameter of 120 nm exhibited
the highest volume-based accumulation rate in the trabecular meshwork, while smaller
particles were superior regarding the delivered particle number. This fact is useful for drug
delivery as it enables particles to selectively target the trabecular meshwork by choosing
the optimal size and thereby reducing off-target effects. Our results additionally suggest
that NPs of about 120 nm can be a useful tool for glaucoma therapy due to their higher
drug encapsulation capacity. Consequently, a lower number of particles will be needed to
elicit a therapeutic effect.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/pharmaceutics13060901/s1, Figure S1: 1H-NMR-spectra of hyaluronic acid and thiolated
hyaluronic acid in comparison, Figure S2: Determination of protein adsorption by using SDS-PAGE,
Figure S3: Aggregated HA-AuNPs, Figure S4: MTT-Assay to determine the cell toxicity.
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